Azoicai Alice Nicoleta, Miron Ingrith, Lupu Ancuta, Alexoae Monica Mihaela, Starcea Iuliana Magdalena, Alecsa Mirabela, Lupu Vasile Valeriu, Danielescu Ciprian, Nedelcu Alin Horatiu, Salaru Delia Lidia, Dragan Felicia, Ioniuc Ileana
Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.
Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.
Front Public Health. 2025 Jan 29;12:1390951. doi: 10.3389/fpubh.2024.1390951. eCollection 2024.
Vaccination is considered to be one of the most effective means of protecting individuals and populations from the risks associated with exposure to various pathogens. The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affected people of all ages worldwide. In response, several pharmaceutical companies rapidly leveraged their resources to develop vaccines within a very short period of time, leading to the introduction of new, improved, and combination vaccines for community-wide immunization. This review aims to provide a summary of the available literature on the efficacy and safety of COVID-19 vaccines in the pediatric population ranging from 0 to 18 years. An analysis of recent published studies reveals that the majority of clinical trials have reported a sustained immune response following COVID-19 vaccination in children across various age groups worldwide. The majority of the authors highlighted the effectiveness and safety of immunization schedules in children and adolescents. The population-level efficacy of this vaccination remains to be determined, provided that the benefits outweigh the potential risks. Long-term side effects must still be monitored to enable the development of safer and more effective vaccines for future pandemics.
疫苗接种被认为是保护个人和人群免受接触各种病原体相关风险的最有效手段之一。由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的新冠疫情影响了全球所有年龄段的人群。作为回应,几家制药公司迅速利用其资源在很短的时间内开发疫苗,从而推出了用于社区免疫的新型、改良型和联合疫苗。本综述旨在总结关于0至18岁儿童群体中新冠疫苗效力和安全性的现有文献。对近期发表研究的分析表明,大多数临床试验报告称,全球各年龄组儿童接种新冠疫苗后都产生了持续的免疫反应。大多数作者强调了儿童和青少年免疫接种计划的有效性和安全性。只要益处大于潜在风险,这种疫苗接种在人群层面的效力仍有待确定。仍必须监测长期副作用,以便为未来的大流行开发更安全、更有效的疫苗。